ArticleExperimental and therapeutic medicine2013
Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion.
Yan Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.